Galectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com

StockNews.com lowered shares of Galectin Therapeutics (NASDAQ:GALT) from a hold rating to a sell rating in a research note published on Thursday.

Separately, HC Wainwright reaffirmed a buy rating and issued a $11.00 price target on shares of Galectin Therapeutics in a research note on Tuesday, April 9th.

Galectin Therapeutics Stock Performance

NASDAQ GALT opened at $2.42 on Thursday. The stock’s fifty day moving average is $2.59 and its two-hundred day moving average is $2.46. The firm has a market capitalization of $150.40 million, a P/E ratio of -3.27 and a beta of 0.63. Galectin Therapeutics has a fifty-two week low of $1.35 and a fifty-two week high of $4.27.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). As a group, sell-side analysts forecast that Galectin Therapeutics will post -0.66 EPS for the current year.

Hedge Funds Weigh In On Galectin Therapeutics

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Galectin Therapeutics by 2.0% during the 1st quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company’s stock worth $4,732,000 after acquiring an additional 38,037 shares in the last quarter. Wealthspire Advisors LLC lifted its stake in Galectin Therapeutics by 116.7% during the 1st quarter. Wealthspire Advisors LLC now owns 398,374 shares of the company’s stock worth $952,000 after acquiring an additional 214,512 shares in the last quarter. Retirement Guys Formula LLC lifted its stake in Galectin Therapeutics by 56.9% during the 1st quarter. Retirement Guys Formula LLC now owns 33,732 shares of the company’s stock worth $81,000 after acquiring an additional 12,232 shares in the last quarter. Finally, Solutions 4 Wealth Ltd acquired a new position in Galectin Therapeutics during the 4th quarter worth about $60,000. Institutional investors and hedge funds own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.